PriceTargets.com logo

Organigram - OGI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$3.13
  • Forecasted Upside: 136.74%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
C$1.32 As of 10/30/2026 05:00 PM ET
▼ -0.05 (-3.65%)

This chart shows the closing price for OGI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Organigram Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OGI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OGI

Analyst Price Target is C$3.13
▲ +136.74% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Organigram in the last 3 months. The average price target is C$3.13, with a high forecast of C$3.25 and a low forecast of C$3.00. The average price target represents a 136.74% upside from the last price of C$1.32.

This chart shows the closing price for OGI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Organigram. This rating has held steady since February 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2026

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/11/2026ATB Cormark Capital MarketsDowngradeStrong-Buy ➝ Moderate BuyC$3.50 ➝ C$3.25
1/27/2026Canaccord Genuity GroupSet TargetBuyC$3.00
12/17/2024ATB Cormark Capital MarketsLower TargetC$5.25 ➝ C$3.50
12/9/2024Canaccord Genuity GroupLower TargetSpeculative BuyC$3.60 ➝ C$3.15
8/14/2024Canaccord Genuity GroupBoost TargetSpeculative BuyC$3.25 ➝ C$3.60
5/17/2024Jefferies Financial GroupLower TargetC$4.40 ➝ C$4.35
5/15/2024Canaccord Genuity GroupLower TargetSpeculative BuyC$3.75 ➝ C$3.25
4/3/2024ATB Cormark Capital MarketsSet TargetOutperformC$5.25
2/27/2024Jefferies Financial GroupLower TargetBuyC$4.95 ➝ C$4.40
2/14/2024Alliance Global PartnersBoost TargetNeutralC$2.00 ➝ C$2.70
12/20/2023ATB Cormark Capital MarketsBoost TargetOutperformC$5.50 ➝ C$6.50
12/20/2023Alliance Global PartnersLower TargetC$2.25 ➝ C$2.00
12/20/2023Canaccord Genuity GroupLower TargetC$4.00 ➝ C$3.75
7/18/2023Haywood SecuritiesLower TargetC$5.00 ➝ C$3.00
7/17/2023Stifel NicolausBoost TargetC$1.25 ➝ C$4.00
7/17/2023Alliance Global PartnersBoost TargetC$1.00 ➝ C$2.25
7/17/2023ATB Cormark Capital MarketsLower TargetC$9.00 ➝ C$6.50
7/17/2023Canaccord Genuity GroupLower TargetC$9.00 ➝ C$4.00
4/21/2023Jefferies Financial GroupLower TargetC$1.80 ➝ C$1.50
4/13/2023ATB Cormark Capital MarketsLower TargetC$2.50 ➝ C$2.25
4/13/2023Canaccord Genuity GroupLower TargetC$3.25 ➝ C$2.25
4/13/2023Haywood SecuritiesLower TargetC$1.60 ➝ C$1.25
4/13/2023Stifel NicolausLower TargetC$1.50 ➝ C$1.25
2/28/2023Jefferies Financial GroupLower TargetC$2.00 ➝ C$1.80
1/13/2023Alliance Global PartnersLower TargetC$1.50 ➝ C$1.30
1/13/2023Stifel NicolausUpgradeHold ➝ Buy
12/23/2022Jefferies Financial GroupLower TargetC$2.60 ➝ C$2.00
8/31/2022Eight CapitalLower TargetC$2.60 ➝ C$1.70
7/19/2022Jefferies Financial GroupLower TargetMarket PerformC$3.34 ➝ C$2.60
7/15/2022Haywood SecuritiesLower TargetHoldC$2.50 ➝ C$1.90
7/15/2022Stifel NicolausLower TargetC$2.25 ➝ C$1.50
4/14/2022Raymond James FinancialSet TargetOverweightC$3.00
4/13/2022Jefferies Financial GroupLower TargetC$3.44 ➝ C$3.34
4/13/2022ATB Cormark Capital MarketsUpgradeSector Perform ➝ OutperformC$3.00
4/12/2022ATB Cormark Capital MarketsUpgradeSector Perform ➝ Outperform
3/15/2022Raymond James FinancialLower TargetOutperformC$5.00 ➝ C$3.00
1/12/2022ATB Cormark Capital MarketsBoost TargetSector PerformC$2.65 ➝ C$3.00
1/12/2022Canaccord Genuity GroupUpgradeHold ➝ Speculative BuyC$3.00 ➝ C$3.25
1/10/2022Raymond James FinancialReiterated RatingOutperformC$5.00
1/7/2022Alliance Global PartnersLower TargetNeutral ➝ UnderperformC$4.00 ➝ C$2.25
12/22/2021Raymond James FinancialReiterated RatingOutperformC$5.00
11/30/2021Jefferies Financial GroupLower TargetMarket PerformC$3.83 ➝ C$3.49
11/25/2021Raymond James FinancialSet TargetOutperformC$5.00
11/24/2021Alliance Global PartnersLower TargetUnderperformC$3.75 ➝ C$3.00
11/24/2021ATB Cormark Capital MarketsLower TargetC$4.25 ➝ C$2.65
11/19/2021Raymond James FinancialSet TargetOutperformC$5.00
(Data available from 10/31/2021 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2026

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Organigram logo
Organigram Global Inc. is listed on the NASDAQ Global Select Market and TSX. The Company's wholly owned subsidiary, Organigram Inc., is a licensed cultivator and processor. Through its acquisition of Sanity Group GmbH ('Sanity Group'), Organigram participates in the German medical cannabis market and other emerging markets within Europe. Organigram is focused on producing high-quality cannabis for adult consumers, as well as extending the Company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, SHRED, Monjour, Tremblant, Collective Project, Trailblazer, BOXHOT and DEBUNK. Through its acquisition of Sanity Group, Organigram's European brands include Vayamed, avaay, ZOIKS, Endosane Pharmaceuticals, VAAY, and Grashaus Projects. Organigram operates facilities in Moncton, New Brunswick and Lac Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
Read More

Today's Range

Now: C$1.32
Low: C$1.31
High: C$1.35

50 Day Range

MA: C$1.47
Low: C$1.28
High: C$1.77

52 Week Range

Now: C$1.32
Low: C$1.20
High: C$3.09

Volume

122,159 shs

Average Volume

188,436 shs

Market Capitalization

C$190.28 million

P/E Ratio

2.20

Dividend Yield

N/A

Beta

1.640023

Frequently Asked Questions

What sell-side analysts currently cover shares of Organigram?

The following Wall Street analysts have issued reports on Organigram in the last year: ATB Cormark Capital Markets, and Canaccord Genuity Group Inc..
View the latest analyst ratings for OGI.

What is the current price target for Organigram?

0 Wall Street analysts have set twelve-month price targets for Organigram in the last year. Their average twelve-month price target is C$3.13, suggesting a possible upside of 136.7%. ATB Cormark Capital Markets has the highest price target set, predicting OGI will reach C$3.25 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of C$3.00 for Organigram in the next year.
View the latest price targets for OGI.

What is the current consensus analyst rating for Organigram?

Organigram currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OGI will outperform the market and that investors should add to their positions of Organigram.
View the latest ratings for OGI.

What other companies compete with Organigram?

Other companies that are similar to Organigram include CanniMed Therapeutics, Tilray Brands, Fennec Pharmaceuticals, Canopy Growth and Valens GroWorks. Learn More about companies similar to Organigram.

How do I contact Organigram's investor relations team?

Organigram's physical mailing address is 145 King Street West, Toronto, ON, M5H 1J8. The company's listed phone number is 844-644-4726. The official website for Organigram is www.organigram.ca. Learn More about contacing Organigram investor relations.